Promoter-Operating Targeted Expression of Gene Therapy in Cancer: Current Stage and Prospect

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Gene therapy for cancer relies on targeted gene expression.
• Various delivery systems (liposomes, nanoparticles, PEI) are documented for cancer gene therapy.
• The role of specific gene promoters in cancer gene therapy remains underexplored.

Purpose of the Study:

• To review the current status of promoter-driven targeted gene expression in cancer gene therapy.
• To identify challenges and problematics in developing effective promoter systems.
• To highlight the therapeutic potential of promoter-controlled gene expression for cancer treatment.

Main Methods:

• Literature review of existing studies on gene therapy delivery systems and promoters.
• Analysis of the challenges in selecting and utilizing specific gene promoters.
• Synthesis of current knowledge on promoter-operating targeted gene expression.

Main Results:

• Extensive literature exists on delivery systems but limited on specific gene promoters for cancer gene therapy.
• Understanding the ideal gene promoter for targeted expression in cancer is a significant hurdle.
• Further development is required to translate promoter-based gene therapy into clinical practice.

Conclusions:

• Optimizing gene promoter selection is crucial for advancing cancer gene therapy.
• Addressing current limitations in promoter technology can enhance therapeutic efficacy.
• Promoter-operating targeted gene expression holds significant promise for future cancer treatments.